Shots:

• The study involves assessing of JHL1266 vs Prolia sourced from the EU and the US in healthy human subjects evaluating its PK- PD- and immunogenicity
• The JHL1266 is proved to be a milestone and an initiative in bringing safe- effective- and high-quality biologics
• JHL1266 is a mAb targeting RANKL works by inhibition of developed osteoclasts and then preventing break down of bones in the human body and is targeted for osteoporosis- bone metastases- giant cell tumors of bone- and other treatment-induced bone loss

Click here to read full press release/ article | Ref: JHL | Image: Behance